CN1262665C - 经过密码子最优化的乳头状瘤病毒序列 - Google Patents

经过密码子最优化的乳头状瘤病毒序列 Download PDF

Info

Publication number
CN1262665C
CN1262665C CNB018161081A CN01816108A CN1262665C CN 1262665 C CN1262665 C CN 1262665C CN B018161081 A CNB018161081 A CN B018161081A CN 01816108 A CN01816108 A CN 01816108A CN 1262665 C CN1262665 C CN 1262665C
Authority
CN
China
Prior art keywords
hpv
polynucleotide sequence
cell
sequence
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018161081A
Other languages
English (en)
Chinese (zh)
Other versions
CN1462309A (zh
Inventor
彼得·F·厄特尔
杰拉尔德·W·高夫
瓦尼塔·帕马
克里斯托弗·J·A·林
萨拉·M·沃尔科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0017990.3A external-priority patent/GB0017990D0/en
Priority claimed from GB0025802A external-priority patent/GB0025802D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1462309A publication Critical patent/CN1462309A/zh
Application granted granted Critical
Publication of CN1262665C publication Critical patent/CN1262665C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018161081A 2000-07-21 2001-07-20 经过密码子最优化的乳头状瘤病毒序列 Expired - Fee Related CN1262665C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0017990.3 2000-07-21
GBGB0017990.3A GB0017990D0 (en) 2000-07-21 2000-07-21 Papilloma virus sequences
GB0025802A GB0025802D0 (en) 2000-10-20 2000-10-20 Papilloma virus sequences
GB0025802.0 2000-10-20

Publications (2)

Publication Number Publication Date
CN1462309A CN1462309A (zh) 2003-12-17
CN1262665C true CN1262665C (zh) 2006-07-05

Family

ID=26244703

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018161081A Expired - Fee Related CN1262665C (zh) 2000-07-21 2001-07-20 经过密码子最优化的乳头状瘤病毒序列

Country Status (22)

Country Link
EP (1) EP1301614B1 (enExample)
JP (1) JP2004504057A (enExample)
KR (1) KR100874552B1 (enExample)
CN (1) CN1262665C (enExample)
AT (1) ATE346947T1 (enExample)
AU (2) AU7569501A (enExample)
BR (1) BR0112637A (enExample)
CA (1) CA2416488A1 (enExample)
CY (1) CY1106334T1 (enExample)
CZ (1) CZ2003180A3 (enExample)
DE (1) DE60124918T2 (enExample)
DK (1) DK1301614T3 (enExample)
ES (1) ES2277605T3 (enExample)
HK (1) HK1056195B (enExample)
HU (1) HUP0300745A3 (enExample)
IL (1) IL154009A0 (enExample)
MX (1) MXPA03000554A (enExample)
NO (1) NO20030219L (enExample)
NZ (1) NZ523683A (enExample)
PL (1) PL365385A1 (enExample)
PT (1) PT1301614E (enExample)
WO (1) WO2002008435A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP1427443A4 (en) * 2001-08-23 2006-03-08 Merck & Co Inc VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
RU2356943C2 (ru) 2003-03-24 2009-05-27 Мерк Энд Ко., Инк. Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) 2004-03-24 2010-05-15 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
GB0700914D0 (en) * 2007-01-18 2007-02-28 Animal Health Inst Polynucleotides and uses thereof
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
PL2139515T5 (pl) 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
SG11201803360UA (en) 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
JP7092662B2 (ja) * 2015-10-30 2022-06-28 チルドレンズ ナショナル メディカル センター ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464936A (en) * 1990-12-21 1995-11-07 Cetus Oncology Corporation Compositions for identification of papillomavirus replication inhibitors
DE4123760C2 (de) * 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
AU766403C (en) * 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.

Also Published As

Publication number Publication date
KR100874552B1 (ko) 2008-12-16
AU2001275695B2 (en) 2005-01-27
DE60124918T2 (de) 2007-08-02
MXPA03000554A (es) 2004-12-13
ES2277605T3 (es) 2007-07-16
EP1301614A1 (en) 2003-04-16
NZ523683A (en) 2004-08-27
PT1301614E (pt) 2007-02-28
IL154009A0 (en) 2003-07-31
HK1056195B (en) 2007-06-22
HUP0300745A2 (hu) 2003-08-28
ATE346947T1 (de) 2006-12-15
AU2001275695B9 (en) 2005-05-26
EP1301614B1 (en) 2006-11-29
DE60124918D1 (de) 2007-01-11
CA2416488A1 (en) 2002-01-31
HK1056195A1 (en) 2004-02-06
BR0112637A (pt) 2003-06-10
KR20030074586A (ko) 2003-09-19
WO2002008435A8 (en) 2002-04-04
NO20030219L (no) 2003-03-20
CN1462309A (zh) 2003-12-17
DK1301614T3 (da) 2007-04-02
HUP0300745A3 (en) 2010-01-28
AU7569501A (en) 2002-02-05
PL365385A1 (en) 2005-01-10
JP2004504057A (ja) 2004-02-12
CZ2003180A3 (cs) 2003-08-13
NO20030219D0 (no) 2003-01-16
WO2002008435A1 (en) 2002-01-31
CY1106334T1 (el) 2011-10-12

Similar Documents

Publication Publication Date Title
EP1301614B1 (en) Codon-optimized papilloma virus sequences
AU2001275695A1 (en) Codon-optimized papilloma virus sequences
Liu et al. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
WO2004076645A2 (en) Compositions and methods for cytomegalovirus treatment
RU2323744C2 (ru) Вакцина против hcv
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
US7132262B2 (en) Papilloma virus sequences
US20150132325A1 (en) Novel compositions and uses therefor
CN102286104B (zh) Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途
EP1846026A2 (en) Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
CN104628871A (zh) 一种重组法氏囊病蛋白工程疫苗的制备
CN100393878C (zh) 疫苗
US20090202584A1 (en) Treatment of epstein-barr virus-associated diseases
CA2395208A1 (en) Nucleic acid vaccination
CN117417457A (zh) PCV2和PCV3融合Cap蛋白二联亚单位疫苗及其制备方法和应用
CN1772892A (zh) Hiv－1病毒样颗粒及其制备方法与用途
RU2312896C2 (ru) Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
CN115569189A (zh) 治疗hpv感染的疫苗组合
US20130017572A1 (en) Codon modified polynucleotide sequences for enhanced expression in a host system
Mažeikė Generation of anticancer vaccine based on virus-like particles
Rainone ROLE OF THE MUCOSAE-ASSOCIATED EPITHELIAL CHEMOKINE (MEC/CCL28) IN THE MODULATION OF THE IMMUNE RESPONSE AGAINST VIRAL INFECTIONS
AU2006322645A1 (en) Treatment of Epstein-Barr Virus-associated diseases
CN101255434A (zh) 疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060705

Termination date: 20100720